• OPEN AN ACCOUNT
Indian Indices
Nifty
24,973.10 104.50
(0.42%)
Sensex
81,425.15 323.83
( 0.40%)
Bank Nifty
54,536.00 319.90
( 0.59%)
Nifty IT
36,183.80 927.90
( 2.63%)
Global Indices
Nasdaq
45,729.90 193.94
(0.43%)
Dow Jones
6,533.40 17.25
(0.26%)
Hang Seng
43,788.68 329.39
(0.76%)
Nikkei 225
9,242.53 21.09
(0.23%)
Forex
USD-INR
88.02 -0.16
(-0.18%)
EUR-INR
103.30 -0.01
(-0.01%)
GBP-INR
119.05 -0.02
(-0.01%)
JPY-INR
0.60 0.00
(-0.34%)

EQUITY - MARKET SCREENER

Ipca Laboratories Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524494
INE571A01038
271.6399623
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
IPCALAB
36.86
33466.12
EPS(TTM)
Face Value()
Div & Yield %
35.79
1
0.3
 

rmc switchgears ltd
DLF Q1 PAT rises 18% YoY to Rs 763-cr
Aug 05,2025
Revenue from operations surged 99.41% year-on-year (YoY) to Rs 2,716.70 crore in the quarter ended 30 June 2025.

EBITDA for the quarter stood at Rs 628 crore, reflecting a YoY growth of 5.19%. However, EBITDA margin declined to 21%, down from 34% recorded in Q1 FY25.

New sales bookings for the quarter came in at Rs 11,425 crore, registering a strong YoY growth of 78%. The company attributed this performance to the robust response for its latest luxury launch, DLF Privana North, which reaffirmed the sustained demand for high-quality developments backed by a strong brand and superior execution.

Collections during the quarter stood at Rs 2,794 crore, while net cash surplus generation was at Rs 1,131 crore.

DLF is primarily engaged in the business of development and sale of residential properties (the 'Development Business') and the development and leasing of commercial and retail properties (the 'Annuity Business'). It has developed more than 185 real estate projects and developed an area more than 352 million square feet (approx.).

The scrip slipped 1.59% to Rs 781 on the BSE.